Bayer’s Kerendia was first approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes in 2021.
The FDA has just expanded the label to treat patients with heart failure, whether they have chronic kidney disease or not.
Click here to read the entire article.